Estrogen receptor positive

Estrogen receptor positive (ER+) is a term used in medicine and oncology to describe cells that have a receptor protein that binds to the hormone estrogen. This is most commonly discussed in the context of breast cancer, as the presence of these receptors can influence the growth of the cancer and the treatment options available.

Overview

ER+ breast cancers are the most common type of breast cancer, accounting for about 70% of all cases. These cancers are often slower growing than other types and are more likely to respond to hormone therapy, such as tamoxifen or aromatase inhibitors.

Diagnosis

The presence of estrogen receptors is determined through a biopsy of the tumor. This can be done either through a surgical biopsy, where a piece of the tumor is removed, or a needle biopsy, where a needle is used to extract cells from the tumor. The cells are then examined under a microscope to determine if they have estrogen receptors.

Treatment

Treatment for ER+ breast cancer often involves hormone therapy. This can include drugs that block the estrogen receptors, such as tamoxifen, or drugs that lower the amount of estrogen in the body, such as aromatase inhibitors. Other treatments, such as chemotherapy, radiation therapy, and surgery, may also be used depending on the stage and aggressiveness of the cancer.

Prognosis

The prognosis for ER+ breast cancer is generally good, especially if the cancer is detected early. However, the cancer can sometimes become resistant to hormone therapy, which can make it more difficult to treat.

See also

• Breast cancer
• Hormone receptor
• Hormone therapy
• Tamoxifen
• Aromatase inhibitor

Estrogen receptor positive Resources
Latest articles Most recent articles Ongoing trials	Wikipedia